top of page

Ring Therapeutics believes that the next great viral vector is a ubiquitous, but little known, family of viruses already found in the body

  • blonca9
  • May 9, 2024
  • 1 min read

Ring CEO Tuyen Ong introduces us to anelloviruses and describes the qualities that could make them compelling delivery vehicles. Animal data presented in an oral presentation at #ASGCT2024 today suggests that they can be re-dosed.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page